The selected drugs include: (i) the CARM1 inhibitor BIIB021 in clinical trial for breast and gastrointestinal tumors; (ii) the MAPK1 activator PEITC in clinical trial for lung and oral cancer; (iii) four CDK4 inhibitors, ABEMACICLIB approved for breast cancer, ALVOCIDIB, MILCICLIB and PHA-793887 in clinical trials for several tumors; (iv) three STAT3 modulators, ERLOTINIB approved for lung cancer, ENMD1198 and ATIPRIMOD in trial for neuroendocrine cancer and multiple myeloma; (v) PILOCARPINE approved for the treatment of presbyopia as an inducer of FOS expression. This evidence concerns the gene FOS and lip and oral cavity carcinoma.